Additional file 2: of Multicenter Phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer: The FLEET study SodaHitoshi MaedaHiromichi HasegawaJunichi TakahashiTakao HazamaShoichi FukunagaMutsumi KonoEmiko KotakaMasahito SakamotoJunichi NagataNaoki ObaKoji MishimaHideyuki 2015 Adverse events in patients treated with cetuximab and oxaliplatin-based chemotherapy. (DOCX 16 kb)